O	0	2	An
O	3	14	association
O	15	17	of
B-intervention	18	27	boswellia
I-intervention	27	28	,
I-intervention	29	36	betaine
I-intervention	37	40	and
I-intervention	41	44	myo
I-intervention	44	45	-
I-intervention	45	53	inositol
I-intervention	54	55	(
I-intervention	55	61	Eumast
I-intervention	61	62	รณ
I-intervention	62	63	s
I-intervention	63	64	)
O	65	67	in
O	68	71	the
O	72	81	treatment
O	82	84	of
O	85	97	mammographic
O	98	104	breast
O	105	112	density
O	112	113	:
O	114	115	a
O	116	126	randomized
O	126	127	,
O	128	134	double
O	134	135	-
O	135	140	blind
O	141	146	study
O	146	147	.

O	148	160	Mammographic
O	161	167	breast
O	168	175	density
O	176	178	is
O	179	180	a
O	181	191	recognized
O	192	196	risk
O	197	203	factor
O	204	207	for
O	208	214	breast
O	215	221	cancer
O	221	222	.

O	223	226	The
O	227	233	causes
O	234	238	that
O	239	243	lead
O	244	246	to
O	247	250	the
O	251	264	proliferation
O	265	267	of
O	268	271	the
O	272	281	glandular
O	282	288	breast
O	289	295	tissue
O	296	299	and
O	299	300	,
O	301	310	therefore
O	310	311	,
O	312	314	to
O	315	317	an
O	318	326	increase
O	327	329	of
O	330	336	breast
O	337	344	density
O	345	348	are
O	349	354	still
O	355	362	unclear
O	362	363	.

O	364	371	However
O	371	372	,
O	373	374	a
O	375	384	treatment
O	385	393	strategy
O	394	396	to
O	397	403	reduce
O	404	407	the
O	408	415	mammary
O	416	423	density
O	424	427	may
O	428	433	bring
O	434	439	about
O	440	444	very
O	445	453	relevant
O	454	462	clinical
O	463	471	outcomes
O	472	474	in
O	475	481	breast
O	482	488	cancer
O	489	499	prevention
O	499	500	.

O	501	504	Myo
O	504	505	-
O	505	513	inositol
O	514	516	is
O	517	518	a
O	519	522	six
O	522	523	-
O	523	527	fold
O	528	535	alcohol
O	536	538	of
O	539	550	cyclohexane
O	550	551	,
O	552	555	has
O	556	563	already
O	564	568	been
O	569	575	proved
O	576	578	to
O	579	587	modulate
O	588	597	different
O	598	606	pathways
O	606	607	:
O	608	620	inflammatory
O	620	621	,
O	622	631	metabolic
O	631	632	,
O	633	642	oxidative
O	643	646	and
O	647	656	endocrine
O	657	666	processes
O	666	667	,
O	668	670	in
O	671	672	a
O	673	677	wide
O	678	683	array
O	684	686	of
O	687	692	human
O	693	701	diseases
O	701	702	,
O	703	712	including
O	713	719	cancer
O	720	723	and
O	724	727	the
O	728	735	genesis
O	736	738	of
O	739	746	mammary
O	747	752	gland
O	753	756	and
O	757	763	breast
O	764	772	diseases
O	772	773	,
O	774	778	like
O	779	787	fibrosis
O	787	788	,
O	789	791	as
O	792	796	well
O	797	799	as
O	800	809	metabolic
O	810	813	and
O	814	823	endocrine
O	824	828	cues
O	828	829	.

O	830	839	Similarly
O	839	840	,
O	841	850	boswellic
O	851	855	acid
O	856	859	and
O	860	867	betaine
O	868	869	(
O	869	874	three
O	874	875	-
O	875	881	methyl
O	882	889	glycine
O	889	890	)
O	891	895	both
O	896	903	inhibit
O	904	916	inflammation
O	917	920	and
O	921	926	exert
O	927	937	protective
O	938	945	effects
O	946	948	on
O	949	955	breast
O	956	966	physiology
O	966	967	.

O	968	973	Based
O	974	976	on
O	977	981	this
O	982	992	scientific
O	993	1003	background
O	1003	1004	,
O	1005	1007	we
O	1008	1020	hypothesized
O	1021	1025	that
O	1026	1027	a
O	1028	1039	combination
O	1040	1049	including
O	1049	1050	,
O	1051	1060	boswellic
O	1061	1065	acid
O	1065	1066	,
O	1067	1074	betaine
O	1075	1078	and
O	1079	1082	myo
O	1082	1083	-
O	1083	1091	inositol
O	1092	1097	would
O	1098	1100	be
O	1101	1105	able
O	1106	1108	to
O	1109	1115	reduce
O	1116	1122	breast
O	1123	1130	density
O	1131	1138	working
O	1139	1141	on
O	1142	1151	different
O	1152	1160	pathways
O	1160	1161	.

O	1162	1164	In
O	1165	1169	this
O	1170	1175	study
O	1175	1176	,
B-total-participants	1177	1184	seventy
I-total-participants	1184	1185	-
I-total-participants	1185	1188	six
B-eligibility	1189	1202	premenopausal
I-eligibility	1203	1208	women
O	1209	1213	were
O	1214	1222	randomly
O	1223	1231	assigned
O	1232	1234	to
O	1235	1238	the
B-control	1239	1246	placebo
O	1247	1250	and
O	1251	1254	the
O	1255	1267	experimental
O	1268	1272	drug
O	1273	1277	arms
O	1278	1279	(
O	1279	1285	Eumast
O	1285	1286	รณ
O	1286	1287	s
O	1287	1288	)
O	1289	1292	for
O	1293	1296	six
O	1297	1303	months
O	1303	1304	.

O	1305	1310	After
O	1311	1312	6
O	1313	1319	months
O	1320	1322	of
O	1323	1332	treatment
O	1332	1333	,
O	1334	1347	statistically
O	1348	1359	significant
O	1360	1370	difference
O	1371	1378	between
O	1379	1382	the
O	1383	1386	two
O	1387	1393	groups
O	1394	1397	was
O	1398	1406	recorded
O	1407	1409	on
O	1410	1413	the
B-outcome	1414	1420	breast
I-outcome	1421	1428	density
I-outcome	1429	1438	reduction
O	1439	1440	(
B-iv-bin-percent	1440	1442	60
I-iv-bin-percent	1442	1443	%
O	1444	1446	vs
O	1446	1447	.
B-cv-bin-percent	1448	1449	9
I-cv-bin-percent	1449	1450	%
O	1450	1451	)
O	1451	1452	,
O	1453	1458	using
O	1459	1471	mammographic
O	1472	1474	as
O	1475	1479	well
O	1480	1482	as
O	1483	1493	ultrasound
O	1494	1505	examination
O	1505	1506	.

O	1507	1518	Preliminary
O	1519	1523	data
O	1524	1533	collected
O	1534	1538	here
O	1539	1543	with
O	1544	1551	support
O	1552	1555	the
O	1556	1564	starting
O	1565	1576	assumptions
O	1576	1577	,
O	1578	1582	that
O	1583	1586	the
O	1587	1598	association
O	1599	1609	comprising
O	1610	1619	boswellic
O	1620	1624	acid
O	1624	1625	,
O	1626	1633	betaine
O	1634	1637	and
O	1638	1641	myo
O	1641	1642	-
O	1642	1650	inositol
O	1651	1664	significantly
O	1665	1672	reduces
O	1673	1680	mammary
O	1681	1688	density
O	1688	1689	,
O	1690	1699	providing
O	1700	1703	the
O	1704	1709	first
O	1710	1718	evidence
O	1719	1722	for
O	1723	1724	a
O	1725	1728	new
O	1729	1732	and
O	1733	1737	safe
O	1738	1746	approach
O	1747	1750	for
O	1751	1754	the
O	1755	1765	management
O	1766	1768	of
O	1769	1781	mammographic
O	1782	1789	density
O	1790	1799	treatment
O	1799	1800	.
